// April 18, 2024
USP’s commitment to ESG considerations for a healthier, more sustainable world
At the U.S.
At the U.S.
The development of generic versions of innovator medicines is a global public health need.
Another public health crisis looms in the wake of the COVID-19 pandemic.
The scale and speed of the global vaccine research and development effort in response to COVID-19